Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 6Prostatic Neoplasms 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Locally Advanced Esophageal or GE Junction Cancer 1Hormone Refractory Prostate Cancer 1Disease 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 71Etoposide 63Topotecan 42Cisplatin 38pembrolizumab 30atezolizumab 26durvalumab 22Paclitaxel 16Nivolumab 14PM 01183 13rovalpituzumab tesirine 11Pemetrexed 11amrubicin 9Ipilimumab 9Injections 9Irinotecan 8AMG 757 8trilaciclib 7etoposide phosphate 6EC regimen 6Drug Therapy 6Docetaxel 6Bevacizumab 6tremelimumab 5MLN 8237 5Gemcitabine 5130-nm albumin-bound paclitaxel 5olaparib 4chiauranib 4budigalimab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Small Cell Lung Carcinoma × gossypol acetic acid × Clear all
NCT00397293 2010-08-24

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Ascenta Therapeutics

Phase 1/2 Completed
36 enrolled
Thoracic

Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡